[Featured Stock] HK Innoen Rises on Expectations of 'K-Cab' License Out

[Asia Economy Reporter Jang Hyowon] HK Innoen is showing strong performance amid expectations for the license-out of its self-developed gastroesophageal reflux disease (GERD) new drug ‘K-CAB’.

As of 10:54 AM on the 1st, HK Innoen is trading at 53,300 KRW, up 1.91% from the previous day.

On this day, Oh Byungyong, a researcher at Hanyang Securities, stated, “K-CAB, a self-developed GERD new drug, has only been on the market for two years and is currently experiencing explosive growth,” adding, “Assuming a market share of 30% within the next 2 to 3 years, K-CAB alone can generate operating profits at the level of a mid-sized pharmaceutical company.”

Researcher Oh also said, “Even excluding K-CAB, HK Innoen has been generating operating profits of 70 to 80 billion KRW annually,” and judged, “Considering the company’s growth potential, the current market capitalization (1.4 trillion KRW) is very inexpensive compared to competitors such as Yuhan Corporation (4.3 trillion KRW), Green Cross Corporation (3.9 trillion KRW), and Hanmi Pharmaceutical (3.3 trillion KRW).”

This content was produced with the assistance of AI translation services.